211 Mt. Airy Road
Tel: (908) 992-6400
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.
With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.
For more information, please visit: www.daiichisankyo.com.
Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.
STOCK EXCHANGE: Tokyo Stock Exchange
STOCK SYMBOL: 4568
416 articles with Daiichi Sankyo
Daiichi Sankyo, Inc. And Eli Lilly and Company Release: Enrollment Completed In Pivotal Phase III Study Comparing Prasugrel To Clopidogrel In Patients With Acute Coronary Syndrome
Daiichi Sankyo, Inc. Announces Filing Of New Drug Application For Amlodipine Besylate / Olmesartan Medoxomil Combination For The Treatment Of Hypertension
Daiichi Sankyo, Inc. Release: New Study Confirms WelChol Improves Glycemic Control In Patients With Uncontrolled Type 2 Diabetes Mellitus On Insulin
Daiichi Sankyo, Inc. Release: First Study To Evaluate WelChol/Ezetimibe And Simvastatin Effect On LDL-C Finds Additional Lipid Parameter Benefits
Daiichi Sankyo, Inc. Release: First Clinical Trial To Demonstrate Colesevelam HCl Plus Stable Oral Antidiabetic Medication Improves Glycemic Control In Patients With Type 2 Diabetes
Daiichi Sankyo, Inc. Release: National Under Pressure(TM) Campaign Provides Patient-Centric Approach To Manage Hypertension
Daiichi Sankyo, Inc. Release: First Data To Show Addition Of A Bile Acid Sequestrant (WelChol, colesevelam HCl) To Statin Therapy Significantly Reduces Median hs-CRP Levels
Eli Lilly and Company And Daiichi Sankyo, Inc. Release: Study Examines Continued Economic Burden Of Acute Coronary Syndrome Despite Standard Medical Interventions